These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

688 related items for PubMed ID: 17001889

  • 1. Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms.
    Aron M, Kapila K, Verma K.
    Indian J Pathol Microbiol; 2006 Jul; 49(3):376-80. PubMed ID: 17001889
    [Abstract] [Full Text] [Related]

  • 2. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms.
    Inohara H, Honjo Y, Yoshii T, Akahani S, Yoshida J, Hattori K, Okamoto S, Sawada T, Raz A, Kubo T.
    Cancer; 1999 Jun 01; 85(11):2475-84. PubMed ID: 10357421
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
    Than TH, Swethadri GK, Wong J, Ahmad T, Jamil D, Maganlal RK, Hamdi MM, Abdullah MS.
    Singapore Med J; 2008 Apr 01; 49(4):333-8. PubMed ID: 18418527
    [Abstract] [Full Text] [Related]

  • 5. [Expression and clinical significance of galectin-3 in well-differentiated thyroid carcinoma].
    Ouyang D, Chen FJ, Wei MW, Yang AK, Chen ZQ, Li QL, Chen YF.
    Ai Zheng; 2005 Nov 01; 24(11):1367-71. PubMed ID: 16552965
    [Abstract] [Full Text] [Related]

  • 6. Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma.
    Maruta J, Hashimoto H, Yamashita H, Yamashita H, Noguchi S.
    Diagn Cytopathol; 2004 Dec 01; 31(6):392-6. PubMed ID: 15540177
    [Abstract] [Full Text] [Related]

  • 7. Galectin-3 is not useful in thyroid FNA.
    Mills LJ, Poller DN, Yiangou C.
    Cytopathology; 2005 Jun 01; 16(3):132-8. PubMed ID: 15924608
    [Abstract] [Full Text] [Related]

  • 8. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications.
    Xu XC, el-Naggar AK, Lotan R.
    Am J Pathol; 1995 Sep 01; 147(3):815-22. PubMed ID: 7677193
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma.
    Jakubiak-Wielganowicz M, Kubiak R, Sygut J, Pomorski L, Kordek R.
    Pol J Pathol; 2003 Sep 01; 54(2):111-5. PubMed ID: 14575419
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Diagnostic utility of galectin-3 in aspirates of thyroid follicular lesions.
    Kim MJ, Kim HJ, Hong SJ, Shong YK, Gong G.
    Acta Cytol; 2006 Sep 01; 50(1):28-34. PubMed ID: 16514837
    [Abstract] [Full Text] [Related]

  • 13. Immunohistochemical localization of galectin-3 in malignant and benign human thyroid tissue.
    Cvejic D, Savin S, Paunovic I, Tatic S, Havelka M, Sinadinovic J.
    Anticancer Res; 1998 Sep 01; 18(4A):2637-41. PubMed ID: 9703921
    [Abstract] [Full Text] [Related]

  • 14. Galectin-3 is a presurgical marker of human thyroid carcinoma.
    Orlandi F, Saggiorato E, Pivano G, Puligheddu B, Termine A, Cappia S, De Giuli P, Angeli A.
    Cancer Res; 1998 Jul 15; 58(14):3015-20. PubMed ID: 9679965
    [Abstract] [Full Text] [Related]

  • 15. The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor.
    Cui W, Lu X, Zheng S, Ma Y, Liu X, Zhang W.
    Clin Lab; 2012 Jul 15; 58(5-6):419-26. PubMed ID: 22783570
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Galectin-3 and CD44v6 positivity by RT-PCR method in fine needle aspirates of benign thyroid lesions.
    Matesa N, Samija I, Kusić Z.
    Cytopathology; 2007 Apr 15; 18(2):112-6. PubMed ID: 17397496
    [Abstract] [Full Text] [Related]

  • 18. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.
    de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpção LV, Metze K, Ward LS.
    Histopathology; 2005 Oct 15; 47(4):391-401. PubMed ID: 16178894
    [Abstract] [Full Text] [Related]

  • 19. Galectin-3 immunodetection may improve cytological diagnosis of occult papillary thyroid carcinoma.
    Pisani T, Vecchione A, Giovagnolii MR.
    Anticancer Res; 2004 Oct 15; 24(2C):1111-2. PubMed ID: 15154632
    [Abstract] [Full Text] [Related]

  • 20. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma.
    Chiappetta G, Tallini G, De Biasio MC, Manfioletti G, Martinez-Tello FJ, Pentimalli F, de Nigris F, Mastro A, Botti G, Fedele M, Berger N, Santoro M, Giancotti V, Fusco A.
    Cancer Res; 1998 Sep 15; 58(18):4193-8. PubMed ID: 9751634
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.